ArticleOPEN ACCESS

Improving FCR immunochemotherapy in CLL

Blood
DOI: 10.1182/blood-2009-10-251249
14Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Byrd and colleagues report on the outcomes of a phase 1/2 study of anti-CD23 monoclonal antibody lumiliximab combined with FCR in patients with refractory/relapsed CLL.

Cite

CITATION STYLE

APA

Robak, T. (2010, January 21). Improving FCR immunochemotherapy in CLL. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2009-10-251249

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free